Xtant Medical Holdings Inc. (XTNT)

[~S.B.A.~]

Institutions are preparing just take a look at the bid. They're making the perfect chart forming support on the 50sma. Lol they are going to run this.

[sure bet]

news is on the way
should increase BONE earnings by ten fold
buy while shares are cheap

[sure bet]

Big news wow this is great news wow go baby go

[Penny Roger$]

~ $BONE ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!

Tricky chart but if you think the bottom is near this could be the start!


$BONE has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~







For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~

What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~


To find other similar posts of "BONE" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "BONE": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=BONE ~
Search Ihub for "BONE" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=BONE ~


For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~


Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~


c

[Summitgains]

Great info! Buying more here on Monday.

[et737]

BONE seeing HEDGE FUND action. This article is a must read for any of you BONE investors.

http://www.insidermonkey.com/blog/bacterin-international-holdings-inc-bone-is-a-new-pick-for-this-hedgie-the-details-176093/


GL

[surf1944]

8:32AM Bacterin International enters into a definitive securities purchase agreement with both existing and new investors to purchase 8.51 mln unregistered shares of its common stock and warrants to purchase ~ 4.25 mln shares of its common stock (BONE) 0.63 : Co announced that it has entered into a definitive securities purchase agreement with both existing and new investors to purchase 8.51 million unregistered shares of its common stock and warrants to purchase approximately 4.25 million shares of its common stock.

Upon closing, the transaction will result in gross proceeds to Bacterin International of ~$4.85 million, before deducting placement agents' fees and offering expenses. Proceeds from the transaction will be used to fund the Company's operations and working capital requirements.

[BooDog]

Cept for Holmes, from Sept. http://finance.yahoo.com/q/it?s=BONE

[BooDog]

Not seeing any insider or institutional selling reported though.

[BooDog]

Looks like the FDA and IG are on the attack on this one.

On February 11, 2013, we received a subpoena from the Office of the Inspector General of the U.S. Department of Health and Human Services (“OIG”) in connection with an investigation into possible false or otherwise improper claims submitted to Medicare. The subpoena requests documents related to physician referral programs operated by the Company, which we believe refers to the Company’s prior practice of compensating physicians for performing certain educational and promotional services on behalf of the Company. This program was discontinued in 2010 and involved payments to only a small number of physicians that we believe were made in accordance with all applicable laws. We intend to cooperate with the OIG’s investigation.

http://www.sec.gov/Archives/edgar/data/1453593/000114420413009504/v335040_8k.htm

On January 29, 2013, we received two warning letters from the FDA related to our procedures to ensure compliance with regulatory requirements. The concerns include (i) procedures for implementing corrective and preventative action; (ii) procedures for receiving, reviewing and evaluating complaints; (iii) procedures related to changes to a specification, method, process or procedure; (iv) procedures to ensure that purchased or otherwise received products or services conform to specified requirements; (v) procedures to control documents; (vi) procedures to identify training needs and to ensure all personnel are trained to adequately perform assigned responsibilities; (vii) procedures related to medical device reporting; (viii) procedures to control product that does not conform to specified requirements; (ix) procedures for finished device acceptance; and (x) marketing materials related to our Elutia wound drain.



The warning letters relate to the July 2012 inspection of our facilities and procedures. Following the July 2012 inspection, the FDA issued two Form 483s identifying certain observations regarding our procedures to ensure compliance with regulatory requirements. We established a schedule to respond to the FDA’s observations, and we have provided timely responses. Although the FDA acknowledged receipt of our response, the content of our response was not considered in the warning letters.



The company is committed to actively working with the FDA to address their concerns. The warning letters do not restrict our ability to continue manufacturing and selling our products, nor do they require the withdrawal of any product from the marketplace. The issuance of the warning letters has no impact on patient safety. We take this matter very seriously, and we are committed to fully resolving any issues or concerns.

http://www.sec.gov/Archives/edgar/data/1453593/000114420413005219/v333580_8k.htm

May still be able to play the technicals but my guess is the institutionals wont be sticking around which may explain the sell off.

[BooDog]

Talk about gap and trap. wowzers.

Price Open

1.45

Previous Close

0.99

Last Change / % Change

1.006 0.016 1.62% 444,082

I haven't done any dd on this in a while, certainly looks like it shouldn't be where it is. Convertibles killing this? seems like.
I'll take a closer look.

only 50 shares premarket 1.15 -1.27, certainly makes the 1.45 appear like a fat finger but it doesn't look like it.

[tasha]

I got out awhile back to just break even .. I am watching from the sidelines now.. The chart is bearish at this time..

[SmurfVA]

I'd just started noticing BONE..what's your feedback on this stock currently Tasha? Still holding position? Still feeling positive Vibe?

[tasha]

Golden cross is in Bone's near future.. Added more today ..

[tasha]

I got in today 1.40 .. Chart looking nice.

[surf1944]

7:30AM Bacterin International's OsteoSponge product generates 'positive' clinical results (BONE) 1.42 : Co announces that the first clinical results using the OsteoSponge product for foot and ankle arthrodesis have been published in "The Journal of Foot & Ankle Surgery." The article reports a multi-center, retrospective analysis of 80 joint fusions in 47 subjects who had undergone foot and ankle fusion procedures utilizing OsteoSponge bone graft. Overall, a fusion rate of 97.5% (78 of 80 joints) was determined by radiographic analysis.

The article reported comparable or greater foot and ankle fusion rates, as judged radiographically, to that reported in the biomedical literature. Additionally, at 12-month post-operative assessment, the authors observed statistically significant improvements in function and pain alleviation at rates greater than those previously reported in biomedical studies.

[inversor86]

Interview with the CEO

http://www.equities.com/tv-updates?s=8PLSKSBP

I don't own this stock, but I watch it, just wanted to pass this on.

[surf1944]

Bacterin International Holdings (BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries. Bacterin's Medical Device division develops, employs and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination.

(click to enlarge)

Insider buys

Guy Cook purchased 5,000 shares on September 11 and 95,451 shares during May 9 - June 8 period. Guy Cook owns 25.2% of the company. Guy Cook serves as a Chairman of the board, CEO and President of the company.
Kent Swanson purchased 27,977 shares on June 11 and currently controls 450,000 shares of the company. Kent Swanson serves as a Director and Compensation Committee Chairman.
Jon Wickwire purchased 20,000 shares on May 8 and currently controls 363,139 shares of the company. Jon Wickwire serves as a Director and Chairman of Corporate Governance and Nominating Committees.

http://seekingalpha.com/article/885411-5-healthcare-companies-with-insider-buying-during-september-2012?source=yahoo

http://www.secform4.com/insider-trading/1453593.htm

[crookedneck]

FYI - I sold BONE on July 19th for a nice 33% profit and moved on. You are right no secrets here either, but it was terribly obvious that you shorted the stock with your continual rants. You might want to disguise that better next time - LOL. Cheers!

[----sgs]

Of course and yes, I am short in the stock. No secrets here but I will upload the pictures asap. They have like a 14 million dollar line of credit out on. Some land behind the middle property is for sale with the real-estate and I pretty sure its not worth anywhere near that! Bozeman is expensive, Belgrade is cheap.

[surf1944]

3. Bacterin International Holdings (BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgerie

http://seekingalpha.com/article/731721-3-pharmaceutical-stocks-making-big-moves-on-wednesday-july-18th?source=yahoo

[crookedneck]

Seller Beware! I would like to see such photos and anything that you can produce to back up anything you posted. As you just stated this is just ONE of the three pieces of land they own in Belgrade and how on earth would you know that their employee are just a bunch of kids who are Tim Cooks friends? Your biggest dead giveaway is your quote "If anyone would like photo's of your sub penny company feel free to post back." FYI BONE is nowhere near a sub penny stock! I mean if you actually live in that area and really know all this, why wouldn't you state as such. Right now it seems as you making all this up. Maybe you have shorted it - who knows, but the fact remains that you have not backed up one single claim with a shred of evidence, it's just purely your biased opinion based on what? Hearsay? or a rumor you want to start to help drive the pps downwards for your personal gain? I am just asking is all, so I can see if anything you have stated is legit.

Cheers!

[surf1944]

Total Cash (mrq): 1.36M
Total Cash Per Share (mrq): 0.03
Total Debt (mrq): 8.57M
Total Debt/Equity (mrq): 95.36
Current Ratio (mrq): 1.72
Book Value Per Share (mrq): 0.21

On secondary watch list: low cash holdings....

[----sgs]

BUYER BEWARE! Tim Cook (Guy Cooks son) was telling everyone that would listen "Don't buy at the first of 2011 wait and then buy because its going to be between $9-$15 by 2012.) I have come to the conclusion that this is a SCAM company set up to juice investors. The company owns ONE of their three pieces of land in Belgrade (horrible location, for sale signs all around, their building that they "produce their product in" has a grand total of two bay doors for their loading dock. I think they are month to month on their leases now.) On top of all this the one property they do own is what they used to secure the 15 million dollar line of credit. It is not uncommon for the family to take local kids from Bozeman to their lake house in Idaho (joy rides on their brand new boats) or in one of their many brand new Audi's. Their from sign says "Bacterin The Biofilm Specialist" and their employees are a bunch of kids who are Tim Cooks friends so who knows if they are actually even doing anything except watching Guy Cook talk people out of their money. If anyone would like photo's of your sub penny company feel free to post back.

[Tails]

Has a competitor come up with something better? What ails this little company?

[skipu]

Is this a good entry price?

[surf1944]

7:22AM On The Wires (WIRES) :Bacterin International (BONE) announced that a peer review article in Dove Press Journal has determined its OsteoSponge allograft exhibits ideal properties for bone regeneration with advantage over autografts as there is no risk of complications at the harvest site or donor pain postoperatively.

[mlkrborn]

Down 20 percent on narrower revenues:
Bacterin Announces Record 2011 Revenue of $30.1 Million; Up 96% Year-over-Year
Conference Call at 4:30pm ET to Discuss Full Year and Fourth Quarter 2011 Results
PR NewswirePress Release: Bacterin International, Inc. – 21 hours ago


RELATED QUOTES
Symbol Price Change
BONE 2.599 -0.771

BELGRADE, Mont., March 22, 2012 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, today announced its financial results for the fourth quarter and full year ended December 31, 2011:

Fourth Quarter 2011 Highlights:

Revenue increased 72% to $9.1 million, compared to the $5.3 million for the fourth quarter of 2010.
Operating loss decreased by 21% to $2.7 million, compared to a loss of $3.4 million in the fourth quarter of 2010.
Two-year study results showed Company's flagship product, OsteoSponge®, equivalence to rhBMP-2 in spinal fusion, an important feature at a time when surgeons are moving away from rhBMP-2 because of concerns over complications. OsteoSponge® has already been used in 100,000 procedures prior to the data announcement and the Company expects this data to help further increase its market share, a substantial opportunity as the leading rhBMP-2 based product generates $800 million a year.
A distribution agreement was signed with Jeil for LeForte Craniomaxillofacial System.
Hospital accounts increased to 616 facilities, an increase of 27% over 484 facilities in Q4 2010.


Full Year 2011 Highlights:

Revenue increased 96% to $30.1 million, compared to $15.4 million for fiscal year 2010.
Operating loss decreased by 25% to $6.5 million, compared to fiscal year 2010.
A $15 million credit facility, with an initial draw of $7 million, was secured with MidCap Financial and Silicon Valley Bank; and approximately $3 million was raised in private placement offerings.
The Company acquired the assets of Robinson MedSurg LLC, a medical device distribution company focused primarily on maxillofacial and craniofacial surgery devices.
Entered into an Equity Purchase Agreement for up to $31 million with Lincoln Park Capital Fund LLC
New executive management talent and management reorganization helped drive the company's most active processing quarter in its history.
A third human acellular biological scaffold, hMatrix®, an acellular dermal scaffold, was launched, which Bacterin plans to initially market for homologous use indications, including abdominal wall repair, breast reconstruction, and wound covering - an addressable market the company estimates exceeds $2.5 billion annually in the U.S.
Signed national group purchasing organization contract for Bacterin Biologics and first for Elutia® Wound Drains with ROi, a recognized leader in health care supply chain management for hospitals and medical practices.
Materially increased the number of medical facilities in which its products are used and began the doubling of operating capacity through installation of new equipment.
Increased donor supply through new agreements with donor agencies
Secured $5 million credit facility with BridgeBank, which was repaid with proceeds from the Midcap financing
Joined Russell 3000, Russell Microcap, and Russell Global Indexes and achieved NYSE Amex listing status.


Management Commentary

"We increased our revenue on a quarterly basis by 21% sequentially, 72% year over year, and 96% for the full year 2011 over the full year 2010, showing accelerating progress," said Guy Cook, Bacterin's chairman and CEO. "While our full year gross margin slid to 70% primarily due to increased discounting on stocking purchase orders and non recurring adjustments and increased reserves, we are poised for overall operating margins to expand considerably as we gain operating leverage from our sales force and largely established infrastructure.

"This quarter, we received further validation of OsteoSponge® from an important two-year study, showing equivalence to rhBMP-2 in spinal fusion," Mr. Cook continued. "We expect sales to grow even more rapidly on the back of this strong data set. We also signed a distribution agreement with Jeil Medical Corporation that will leverage our direct sales force, providing additional craniomaxillofacial (CMF) product, to sell into the same call points.

"Our products target markets that in aggregate amount to several billion dollars in annual revenue, which provides significant runway for us to capture share and grow quickly," Mr. Cook added. "Our proprietary processing technology is also a unique asset that we believe provides shareholder value. The key driver of our revenue growth in 2012 will once again be the Osteo family of products, supported by the acceleration of hMatrix, medical device, and royalty revenue. With an increase in our sales force, the new data validation and distribution agreement adding even more product to sell, we remain comfortable with our previously stated expectation of $53 million to $56 million in revenue in 2012."

Q4 2011 Financial Results

Revenue for the quarter was a record $9.1 million, up 21% from the previous quarter, and an increase of 72% compared to $5.3 million in the fourth quarter of 2010. The increase in revenue was primarily attributed to the company's continued market penetration, driven by unique product benefits for both the patient and medical care provider, combined with the continued expansion of the company's direct sales force.

Cost of sales in the fourth quarter included the following:

Non recurring increase in fourth quarter Cost of Sales of $795,000 for the write off of a related party receivable from West Coast Tissue Services (one of Bacterin's donor agencies). In December of 2011, Bacterin signed a four-year extension with West Coast Tissue. In exchange for the extension and a related right of first refusal on donors, the Company agreed to write off the receivable and included the $795,000 write off in Cost of sales in the fourth quarter of 2011.
Bacterin increased its inventory reserve on quarantined inventory by $200,000 for tissue it received back from customers in connection with a voluntary market withdrawal of products during 2011. The FDA is still reviewing whether or not we will be able to release the product but the Company established the reserve in order to be conservative.
Non recurring write off $200,000 of scrap inventory of CMF medical device inventory during the quarter
The Company performed a detailed review of the corporate overhead being applied to its inventory and decided to increase the percentage of general and administrative expenses being allocated to cost of sales on increased production and during the quarter made an adjustment to decrease its general and administrative expenses by $360,000 and increase cost of sales.


Fourth Quarter 2011 EBITDA loss was $1.5 million compared to an EBITDA loss of $316,000 in the prior quarter and an EBITDA loss of $2.7 million in the fourth quarter of 2010. Excluding the non-recurring write off of the West Coast Tissue Accounts Receivable of $795,000 and inventory reserve and write offs of $400,000, fourth quarter 2011 negative EBITDA was $354,000, unchanged from the prior quarter. This was largely due to an increase in our allowance for doubtful accounts on a stocking order sale made in 2011.

Gross profit margin for the quarter was 44%, as compared to 83% in the previous quarter and 82% in the year-ago quarter. Excluding the above adjustments, Q4 2011 gross margin would have been 58% of sales. The decrease in Q4 2011 gross margin (excluding the above items) compared to prior quarters is due to an increased sales discount on $1.4 million of stocking order sales during the quarter and the increase of corporate general and administrative expenses allocated to cost of sales due to increased production.

Operating expenses for the quarter totaled $6.7 million, as compared to $7.8 million in the previous quarter, and $7.1 million in the fourth quarter of 2010. Operating loss for the quarter was $2.7 million, compared to $1.6 million in the previous quarter, and $3.4 million in the fourth quarter of 2010. Net loss was $4.4 million or $(0.11) per basic share for the quarter. This compares to a net loss of $3.2 million or $(0.08) per basic share in the previous quarter, and a net loss in fourth quarter of 2010 of $6.7 million or $(0.18) per basic share.

Cash and cash equivalents and net accounts receivable was $7.8 million at December 31, 2011, compared to a total of $3.8 million at December 31, 2010.

Full Year Financial Results

Revenue for the year ended December 31, 2011 was a record $30.1 million, up 96%, compared to $15.4 million for the full year in 2010. Gross profit margin was 70%, compared to 78% in the previous year. Excluding the cost of sales adjustments, FY 2011 gross margin would have been 74% of sales. Operating expenses for the year totaled $27.5 million, compared to $20.7 million in the previous year. Operating loss for the year was $6.5 million, compared to $8.6 million in the previous year. Net loss was $3.0 million or $(0.08) per basic share for the year. This compares to a net loss of $19.5 million or $(0.61) per basic share for the previous year.

EBITDA for the year totaled a loss of $3.0 million, compared EBITDA loss of $5.8 million in 2010.

Conference Call Details:

[Penny Roger$]

~ Thursday! $BONE ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $BONE ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=BONE&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=BONE&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=BONE
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=BONE#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=BONE+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=BONE
Finviz: http://finviz.com/quote.ashx?t=BONE
~ BusyStock: http://busystock.com/i.php?s=BONE&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=BONE >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[gurupup]

I spoke to one of the world's leading orthopods, probably #1 or #2. He saw BONE last year and was very impressed. He spent a lot of time at their booth this year and was blown away this time. He believes BONE has a opportunity to screw it up or control their destiny to the top of the industry. He has used their products, and has switched exclusively to them, and what he sees now is out of sight.

I used to own a ton of BONE close to 5%, sold a lot and am buying it all back. My bet is that it is sold at 6-7X 2013 revs of $75m +++.

[gurupup]

Great read and information here from AAOS.

https://www.rdocs.com/getrdocnologin.asp...

[surf1944]

1:07AM Bacterin International presents study showing OsteoSponge equivalence to rhBMP-2 in spinal fusion (BONE) 2.74 : Co announces it presented a study showing OsteoSponge equivalence to rhBMP-2 in spinal fusion. The two-year prospective, randomized, and blinded clinical data showed OsteoSponge to be equivalent to rhBMP-2 in achieving an interbody fusion based upon radiographic assessment, CT scans, and quality of life outcomes. Additionally, patients receiving the OsteoSponge graft reported statistically significant less leg pain at one year relative to the rhBMP-2 group.

[surf1944]

Bacterin to Present at the Noble 8th Annual Equity Conference on January 17, 2012
PR NewswirePress Release: Bacterin International Holdings, Inc. –

BELGRADE, Mont. , Jan. 11, 2012 /PRNewswire/ --Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, has been invited to present at the Noble Financial Capital Markets' 8th Annual Equity Conference. The conference will be held at the Hard Rock Hotel & Casino in Hollywood, Florida on January 17-18, 2012 .

Bacterin's chairman and CEO, Guy Cook , is scheduled to present on Tuesday, January 17, 2012 at 1:00 p.m. Eastern time , with one-on-one meetings held throughout the day. Management will discuss Bacterin's business plan and objectives for 2012.

The presentation will be video webcast live and available for replay here, or via the investor relations section of Bacterin's website at www.bacterin.com.

Bacterin reported record revenue of $7.5 million in the third quarter 2011, up 80% year-over-year. For 2012, management expects revenue of $53 million to $56 million .

The conference will showcase approximately 140 small and micro cap companies. Presenting companies encompass four general sectors: Healthcare, Technology, Software, Defense and Media/Entertainment.

For more information about the conference, please contact your Noble Financial sales representative.

[ICEQUITY]

(AMEX: $BONE) @StockNotifier Guy Cook of Bacterin International Holdings discusses with Equities.com the innovation behind anti-infective coatings and bone graft material that the company provides for the healthcare market.
http://bit.ly/BONE-EQUITIES

Register For Free - DD
http://www.equities.com/user/register/stocknotifier

[surf1944]

1:21PM Bacterin International study shows OsteoSponge equivalence to rhBMP-2 in spinal fusion (BONE) 2.80 +0.01 : Used in conjunction with the patients' own bone marrow aspirate, OsteoSponge is a highly effective osteoinductive and osteoconductive bone scaffold that aids in spinal fusion. The study was conducted in collaboration with researchers at the Salt Lake Orthopaedic Clinic, Spine Surgery of Salt Lake City. The two-year post-operative, clinical data showed OsteoSponge to be equivalent to rhBMP-2 in achieving an interbody fusion based upon radiographic assessment, CT scans, and quality of life outcomes. Additionally, patients receiving the OsteoSponge graft reported statistically significant less leg pain at one year relative to the rhBMP-2 group

[windansea]

hi surf - thanks for the insider sources. Just doubled up on my position @ $2.00 a few days ago. Hope this baby is on the move. Looks like a "rounded bottom". No big jump in volume though. Hope someone will post some good new fundamental DD on this board. GL to longs.

[surf1944]

http://www.insidercow.com/history/company.jsp?company=bone&B1=Search%21

http://www.secform4.com/insider-trading/1453593.htm

http://www.form4oracle.com/company/bacterin-international-holdings-inc-bone?id=14528

[Devilseye]

Some thing is up looks like it's moving up

[windansea]

Anybody out there?? This thing looks like it is finally moving.
Unfortunately, volume is not very impressive.

[windansea]

Just took on a small position. Unique board = no pumpers, no bashers, just facts. Keep up the good work.

[surf1944]

8:31AM Bacterin International secured a 42-month credit facility from MidCap Financial and Silicon Valley Bank that provides a line of credit up to $15 million (BONE) 2.38 : Co received a first tranche of $7 million at closing to retire all existing indebtedness with Bridge Bank and Western Technology Investments, with the remaining net cash proceeds of approximately $1.4 million to be used for working capital. A second tranche of $8 million is available for potential future acquisitions

[surf1944]

8:32AM Bacterin International acquired the assets of Robinson MedSurg (BONE) 2.32 : For consideration of $1 million in Bacterin common stock at the closing date, Bacterin acquired ~$500,000 in inventory, existing commercial agreements and intellectual property, including a number of patents and patent applications. Upon the achievement of certain revenue goals generated by the assets over a two-year period, additional Bacterin common stock valued at $1 million will be paid to RMS. "We expect to be the only company in the space that can offer this technology with anti-microbial coatings, which we believe has an estimated $600 million market potential.

[surf1944]

Bacterin Joins Russell 3000, Russell Microcap, and Russell Global Indexes

Press Release Source: Bacterin International Holdings, Inc. On Monday June 27, 2011, 8:30 am EDT

BELGRADE, Mont., June 27, 2011 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and anti-infective coatings for medical applications, was added to the U.S. broad-market Russell 3000® Index after the market closed on June 24, 2011. The company was also added to the Russell Microcap® Index and Russell Global Index.

Annual reconstitution of Russell's U.S. indexes captures and ranks the 4,000 largest U.S. stocks as of the end of May by total market capitalization. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index, as well as the appropriate growth and value style indexes. Membership in the Russell Microcap Index, which also remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.

"Our addition to these Russell indexes represents another major milestone for Bacterin," said Guy Cook, the company's chairman and CEO. "It reflects that we're at a pivotal stage in our development in terms of our sales expansion and profitability. After double-digit sequential revenue gains over the last seven quarters, the greater visibility and awareness this listing is expected to bring couldn't come at a more favorable point in our development."

The Russell 3000 also serves as the U.S. component to the Russell Global Index. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $3.9 trillion in institutional assets currently are benchmarked to them. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.

About Russell

Russell Investments provides strategic advice, world-class implementation, state-of-the-art performance benchmarks and a range of institutional-quality investment products. Russell has about $161 billion in assets under management as of March 31, 2011, and serves individual, institutional and advisor clients in more than 35 countries. Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life Insurance Company. More information about Russell Indexes, including total returns, is available at http://www.russell.com/Indexes/data/default.asp.

[surf1944]

Form 8-K for BACTERIN INTERNATIONAL HOLDINGS, INC.

14-Jul-2011

Entry into a Material Definitive Agreement, Completion of A


ITEM 1.01 Entry into a Material Definitive Agreement

On July 11, 2011, the Company signed an Asset Purchase Agreement ("Agreement") with Robinson MedSurg, LLC ("Seller"), a company engaged in the manufacture, distribution and sale of implantable medical devices for maxillofacial, craniofacial and orthopedic uses. Under the terms of the Agreement, the Company purchased certain assets from Seller, as described in the Agreement, for $1 million in common stock of the Company. In addition, the Company agreed to pay Seller an additional $500,000 in common stock when gross revenue from the sale of products resulting from the purchased assets ("Products") equals or exceeds $1 million, and an additional $500,000 in common stock when gross revenue from the sale of Products equals or exceeds $2 million, provided that such gross revenue thresholds are achieved within 2 years. The Company also engaged the sole member of Seller as a consultant.

The foregoing description of the Agreement is qualified in its entirety by reference to the full text of the Agreement, a copy of which is attached hereto as Exhibit 10.17 and incorporated by reference herein.



ITEM 2.01 Completion of Acquisition or Disposition of Assets

The information contained in Item 1.01 of this Form 8-K is incorporated by reference into this Item 2.01.



ITEM 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Our Certificate of Incorporation was amended pursuant to a vote of our shareholders at our Annual Meeting held on July 8, 2011. The amendment authorizes the classification of our Board of Directors into three classes with staggered terms and was proposed in our proxy statement filed with the Securities and Exchange Commission on June 8, 2011. The amendment was effective when filed with the Delaware Secretary of State on July 11, 2011 and is attached hereto as Exhibit 3.1.



ITEM 5.07 Submission of Matters to a Vote of Security Holders

We held our annual meeting of stockholders at 2:30 p.m. local time on July 8, 2011 at the offices of Granus Financial, 1120 Avenue of the Americas, 4th Floor, New York, NY 10036 to vote on the following matters:

1. Classified Board Amendment

An amendment to the Company's certificate of incorporation to authorize the classification of the Company's Board of Directors into three classes with staggered terms was approved according to the voting results listed below:

For Against Abstain

21,251,525 217,862 2,540

2. Election of Directors

All of the following nominees were elected to the Company's Board of Directors in either Class I, Class II or Class III, with Class I directors to serve until the 2012 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified, Class II directors to serve until the 2013 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified, and Class III directors to serve until the 2014 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified.

Nominee For Withheld
Class I Guy Cook 20,849,266 622,661
Class I Mitchell Godfrey 21,299,280 172,647
Class II Kent Swanson 20,849,430 622,497
Class III Michael Lopach 20,864,430 607,497
Class III Jon Wickwire 20,849,430 622,497


3. Ratification of the Company's Independent Auditors

Stockholders ratified the appointment of Ehrhardt, Keefe, Steiner & Hottman PC as the independent auditors of the Company for the fiscal year ended December 31, 2011, in accordance with the voting results listed below.

For Against Abstain

24,032,811 84,678 22,486

4. Approval of Amended and Restated Bacterin International Equity Incentive Plan

Stockholders approved the amendment to the Company's Equity Incentive Plan to increase the number of shares of the Company's common stock reserved for issuance under the plan to 9,000,000 shares, in accordance with the voting results listed below.

For Against Abstain

20,604,318 789,109 78,500



http://biz.yahoo.com/e/110714/bone8-k.html

[surf1944]

Bacterin International: A Biotech Heading Toward Profitability

http://seekingalpha.com/article/272567-bacterin-international-a-biotech-heading-toward-profitability?source=yahoo

[surf1944]

Bacterin International Receives $1 million Initial Investment of $31 Million Purchase Agreement with Lincoln Park Capital Fund, LLC

Press Release Source: Bacterin International Holdings, Inc. On Tuesday May 31, 2011, 8:15 am EDT

BELGRADE, Mont., May 31, 2011 /PRNewswire/ -- Bacterin International Holdings, Inc. ("Bacterin") (NYSE Amex: BONE), a creator and developer of revolutionary bone graft material and anti-infective coatings for medical applications, today announced that it has entered into an equity purchase agreement with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago based asset management firm. Under the terms of the agreement, Bacterin received an initial investment of $1 million through the sale of shares of its common stock to LPC at $3.06 per share, a price per share equal to the closing price on May 26th, 2011, together with warrants to purchase an additional 130,719 shares at the same price per share, subject to NYSE Amex approval. These terms are consistent with the Company's previously announced equity capital raise of up to $3.5 million, of which $1,874,502 was raised prior to LPC's investment. With LPC's investment and an additional $153,000 that was recently raised from outside third parties, subject to NYSE Amex approval, a total of approximately $3,027,504 has been raised at a valuation consistent with the market price of the stock.

In addition, LPC has committed to invest, up to an additional $30 million through the purchase of shares of Bacterin's common stock from time to time over the next three years. The transactions will be at Bacterin's sole option with no additional warrants granted.

During the 36-month term of the agreement, Bacterin has the right to sell to LPC up to an additional $30 million of its common stock, subject to certain conditions, which include the effectiveness of a registration statement with the U.S. Securities and Exchange Commission covering the sale of the shares that may be issued to LPC. There are no upper limits to the price LPC may pay to purchase Bacterin common stock and the purchase price of the shares related to any future investments will be based on the prevailing market prices of Bacterin's common shares immediately preceding the notice of sale to LPC without any fixed discount. The Company controls the timing and amount of any future investment and LPC is obligated to make purchases, if and when the Company decides, in accordance with the purchase agreement. There are no penalties or liquidated damages in the purchase agreement. The agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty.

A more detailed description of the agreement is set forth in the Company's Current Report on Form 8-K recently filed with the SEC on May 31, 2011 which the Company encourages to be reviewed carefully. The securities offered have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

[surf1944]

Russell Announces 2011 Changes: New Additions Should Benefit

http://seekingalpha.com/article/274440-russell-announces-2011-changes-new-additions-should-benefit?source=yahoo

[surf1944]

BONE to be added to the Russell index:

http://www.russell.com/indexes/tools-resources/reconstitution/reconstitution-changes.asp

[sdy]

BONE will present at SEVEN; Noble Financial Capital Markets' May 16, 2011

BELGRADE, Mont., May 4, 2011 -- /PRNewswire/ -- Bacterin International Holdings, Inc. ("Bacterin") (NYSE Amex: BONE), a developer of revolutionary bone graft material, today announced that its chairman and CEO, Guy Cook, will present at SEVEN; Noble Financial Capital Markets' Seventh Annual Equity Conference at the Hard Rock Hotel in Hollywood, Florida, on Monday, May 16, 2011 at 4:00p.m. Eastern Time.

At the time of the presentation, a live audio and high-definition video webcast of Bacterin's presentation and a copy of the presentation materials will be available on the Company's website www.bacterin.com, or through the Noble Financial websites: www.noblefcm.com, or www.noble7.com. Bacterin recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will also archived on the Bacterin website for 90 days following the event.

About Bacterin International Holdings, Inc.

BACTERIN INTERNATIONAL HOLDINGS, INC. ("the "Company" or "Bacterin") develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold and promote bone and other tissue growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops anti-microbial coatings based upon proprietary coating technologies. Bacterin develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. Headquartered in Belgrade, Montana, Bacterin operates a 32,000 square foot, state-of-the-art, fully compliant and FDA registered facility, equipped with five "Class 100" clean rooms. For further information please visit www.bacterin.com.

About Noble Financial

Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service, investment banking boutique focused on small-cap, emerging growth companies. The company has offices in New York, Boston, New Jersey, St Louis, and Boca Raton. In addition to non-deal road shows and sector-specific conferences throughout the year, Noble Financial hosts its large format annual equity conference in late spring featuring 120 – 150 presenting companies from across North America and total attendance of close to 600. For more information: www.noblefcm.com

[sdy]

BONE Launches Third Biologic Scaffold

BELGRADE, Mont., May 5, 2011

BELGRADE, Mont., May 5, 2011 /PRNewswire/ -- Bacterin International Holdings, Inc. ("Bacterin") (NYSE Amex: BONE), a creator and developer of revolutionary bone graft material and antimicrobial coatings for medical applications, today announced that it is commencing distribution of the Company's third human acellular biological scaffold, hMatrix®, an acellular dermal scaffold.

Bacterin's hMatrix® is an acellular matrix processed from donated human dermal tissue that is used to replace damaged tissue or repair, reinforce or supplementary support soft tissue defects. hMatrix® retains the natural structure of dermis to promote cellular ingrowth, tissue vascularization, and regeneration. In line with the Company's focus on providing safe products, hMatrix® will be distributed as a sterile product. The Company initially intends to market the product for homologous use indications, including abdominal wall repair, breast reconstruction, and for wound covering – a market size estimated by the company to exceed $2.5 billion, annually in the U.S.

"Our open dialog with the surgeons that use our OsteoSponge® products provided us with invaluable input and recommendations to encourage us to enter this large dermal scaffold market," commented Guy Cook, chairman and CEO of Bacterin. "We have been able to quickly adapt our core technology and, over the past six months, were able to leverage our manufacturing processes, donor supply, and sales effort to support the commercialization of this important new product line. We are excited to be expanding our biologic portfolio and product offerings into this call point, for which we have received a great deal of interest, and are very optimistic of its revenue potential."

About Bacterin International Holdings, Inc.

BACTERIN INTERNATIONAL HOLDINGS, INC. ("the "Company" or "Bacterin") develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold and promote bone and other tissue growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops antimicrobial coatings based upon proprietary coating technologies. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. Headquartered in Belgrade, Montana, Bacterin operates a 32,000 square foot., state-of-the-art, fully compliant and FDA registered facility, equipped with five "Class 100" clean rooms. For further information please visit www.bacterin.com.